Business · 01/07/2016Updated: 10/17/2026 · 1 min read
FDA Announces Public Workshop on Erythropoietic Protoporphyria to Discuss Potential Drug Therapies
Summary
The FDA is hosting a public workshop to gather input from patients, healthcare providers, and industry experts on developing safe and effective treatments for Erythropoietic Protoporphyria, a condition that affects daily life, and to discuss the clinical development of potential therapies.